Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study.
Vitale A, Kim JS, Cabibbo G, Casadei-Gardini A, Iavarone M, Rimassa L, Ponziani FR, Tovoli F, Chon HJ, Kang B, Kim C, Imaoka H, Ikeda M, Kudo M, Aoki T, Tortora R, Guarracino M, Stefanini B, Marseglia M, Sparacino A, Celsa C, Bruccoleri M, Alimenti E, Marra F, Campani C, Bhoori S, Mazzaferro V, Sacco R, Facciorusso A, Martini A, Stella L, Cerrito L, Toyoda H, Yasuda S, Rossari F, Rimini M, Suda G, Sho T, Masi G, Vivaldi C, Pressiani T, Kakizaki S, Naganuma A, Avallone A, Nappi A, Vidili G, Soldà C, Bergamo F, Pinato DJ, Pelizzaro F, Foschi FG, Secomandi A, Verderame F, Bronte E, Martinelli E, Marino D, Grasselli S, Olivani A, Brunetto MR, Damone F, Mega A, Marzi L, Tamburini E, Ramundo M, Federico P, Daniele B, Giannini EG, Pasta A, Morisco F, Guarino M, Hoyek C, Boninsegna S, Gupta A, Sacerdoti D, Dalbeni A, Calvo Ramos I, Adeva J, Saitta C, Pitrone C, Lentini Graziano ML, Farella N, Rendina M, Grassi T, Rodriquenz MG, Maiello E, Presa J, Pinho I, Hiasa Y, Hirooka M, Chen J, Arrichiello G, Aschele C, Furlanetto A, Cillo U.
Vitale A, et al. Among authors: kim js.
Liver Cancer. 2025 Aug 5. doi: 10.1159/000547792. Online ahead of print.
Liver Cancer. 2025.
PMID: 41063731
Free PMC article.
